REPORT ID 4536

EMEA (Europe, Middle East and Africa) Fatty Liver Disease Drug Market Report 2017

Publish Date
18-Dec-17
Pages
102
Format
Electronic (PDF)

In this report, the EMEA Fatty Liver Disease Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Fatty Liver Disease Drug for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Fatty Liver Disease Drug market competition by top manufacturers/players, with Fatty Liver Disease Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Conatus Pharmaceuticals
    Novartis
    Intercept Pharmaceuticals
    Allergan
    Immuron
    Takeda
    Gilead Sciences
    Genfit

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    By Type 1
        Granulocyte Colony Stimulating Factor Drug
        Opioid Antagonist Drug
        Pentoxifylline Drug
        Glucocorticoid Drug
    By Type 2
        Alcoholic Fatty Liver
        Non Alcoholic Fatty Liver

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Fatty Liver Disease Drug Market Report 2017
1 Fatty Liver Disease Drug Overview
    1.1 Product Overview and Scope of Fatty Liver Disease Drug
    1.2 Classification of Fatty Liver Disease Drug
        1.2.1 EMEA Fatty Liver Disease Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Fatty Liver Disease Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Granulocyte Colony Stimulating Factor Drug
        1.2.4 Opioid Antagonist Drug
        1.2.5 Pentoxifylline Drug
        1.2.6 Glucocorticoid Drug
    1.3 EMEA Fatty Liver Disease Drug Market by Application/End Users
        1.3.1 EMEA Fatty Liver Disease Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Medical Center
    1.4 EMEA Fatty Liver Disease Drug Market by Region
        1.4.1 EMEA Fatty Liver Disease Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Fatty Liver Disease Drug (2012-2022)
        1.5.1 EMEA Fatty Liver Disease Drug Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Fatty Liver Disease Drug Revenue and Growth Rate (2012-2022)

2 EMEA Fatty Liver Disease Drug Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Fatty Liver Disease Drug Market Competition by Players/Manufacturers
        2.1.1 EMEA Fatty Liver Disease Drug Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Fatty Liver Disease Drug Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Fatty Liver Disease Drug Sale Price by Players (2012-2017)
    2.2 EMEA Fatty Liver Disease Drug (Volume and Value) by Type/Product Category
        2.2.1 EMEA Fatty Liver Disease Drug Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Fatty Liver Disease Drug Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Fatty Liver Disease Drug Sale Price by Type (2012-2017)
    2.3 EMEA Fatty Liver Disease Drug (Volume) by Application
    2.4 EMEA Fatty Liver Disease Drug (Volume and Value) by Region
        2.4.1 EMEA Fatty Liver Disease Drug Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Fatty Liver Disease Drug Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Fatty Liver Disease Drug Sales Price by Region (2012-2017)

3 Europe Fatty Liver Disease Drug (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Fatty Liver Disease Drug Sales and Value (2012-2017)
        3.1.1 Europe Fatty Liver Disease Drug Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Fatty Liver Disease Drug Revenue and Growth Rate (2012-2017)
    3.2 Europe Fatty Liver Disease Drug Sales and Market Share by Type
    3.3 Europe Fatty Liver Disease Drug Sales and Market Share by Application
    3.4 Europe Fatty Liver Disease Drug Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Fatty Liver Disease Drug Sales Volume by Countries (2012-2017)
        3.4.2 Europe Fatty Liver Disease Drug Revenue by Countries (2012-2017)
        3.4.3 Germany Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        3.4.4 France Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        3.4.5 UK Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        3.4.6 Russia Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        3.4.7 Italy Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)

4 Middle East Fatty Liver Disease Drug (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Fatty Liver Disease Drug Sales and Value (2012-2017)
        4.1.1 Middle East Fatty Liver Disease Drug Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Fatty Liver Disease Drug Revenue and Growth Rate (2012-2017)
    4.2 Middle East Fatty Liver Disease Drug Sales and Market Share by Type
    4.3 Middle East Fatty Liver Disease Drug Sales and Market Share by Application
    4.4 Middle East Fatty Liver Disease Drug Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Fatty Liver Disease Drug Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Fatty Liver Disease Drug Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        4.4.4 Israel Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        4.4.5 UAE Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        4.4.6 Iran Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)

5 Africa Fatty Liver Disease Drug (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Fatty Liver Disease Drug Sales and Value (2012-2017)
        5.1.1 Africa Fatty Liver Disease Drug Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Fatty Liver Disease Drug Revenue and Growth Rate (2012-2017)
    5.2 Africa Fatty Liver Disease Drug Sales and Market Share by Type
    5.3 Africa Fatty Liver Disease Drug Sales and Market Share by Application
    5.4 Africa Fatty Liver Disease Drug Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Fatty Liver Disease Drug Sales Volume by Countries (2012-2017)
        5.4.2 Africa Fatty Liver Disease Drug Revenue by Countries (2012-2017)
        5.4.3 South Africa Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Fatty Liver Disease Drug Sales and Growth Rate (2012-2017)

6 EMEA Fatty Liver Disease Drug Manufacturers/Players Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Conatus Pharmaceuticals
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Conatus Pharmaceuticals Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Intercept Pharmaceuticals
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Intercept Pharmaceuticals Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Allergan
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Allergan Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Immuron
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Immuron Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Takeda
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Takeda Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Gilead Sciences
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Gilead Sciences Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Genfit
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Fatty Liver Disease Drug Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Genfit Fatty Liver Disease Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Fatty Liver Disease Drug Manufacturing Cost Analysis
    7.1 Fatty Liver Disease Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Fatty Liver Disease Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Fatty Liver Disease Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Fatty Liver Disease Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Fatty Liver Disease Drug Market Forecast (2017-2022)
    11.1 EMEA Fatty Liver Disease Drug Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Fatty Liver Disease Drug Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Fatty Liver Disease Drug Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Fatty Liver Disease Drug Price and Trend Forecast (2017-2022)
    11.2 EMEA Fatty Liver Disease Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Fatty Liver Disease Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Fatty Liver Disease Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Fatty Liver Disease Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Fatty Liver Disease Drug Sales Forecast by Type (2017-2022)
    11.7 EMEA Fatty Liver Disease Drug Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer